NDANASALSPRAY, METERED
Approved
Jun 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
6/8 — Strong
GIMOTI (metoclopramide hydrochloride) by Pfizer is gastric, biliary, or pancreatic secretions. Approved for nausea and vomiting. First approved in 2020.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GIMOTI is a nasal spray formulation of metoclopramide hydrochloride approved in 2020 for nausea and vomiting. It works by sensitizing tissues to acetylcholine, increasing gastric contractions, relaxing the pyloric sphincter, and accelerating gastric emptying and intestinal transit. The mechanism also increases lower esophageal sphincter tone, making it effective for gastroesophageal reflux and diabetic gastroparesis.
$0.003BPart D
Peak12.5 years to LOEProduct is at peak lifecycle with modest Part D spending ($3M, 1,457 claims in 2023) and minimal competitive pressure, suggesting a stable but niche commercial team focused on market maintenance.
Mechanism of Action
gastric, biliary, or pancreatic secretions. The exact mechanism of action of metoclopramide in the treatment of gastroesophageal reflux and acute and recurrent diabetic gastroparesis has not been fully established. It seems to sensitize tissues to the action of acetylcholine. The effect of…
Indications (1)
Worked on GIMOTI at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.